Trade Names:Amytal Sodium- Powder for injection 500 mg
Amytal (Canada)Depresses sensory cortex; decreases motor activity; alters cerebellar function and produces drowsiness, sedation and hypnosis.
Rapidly distributed to all tissues and fluids, with high concentrations in brain, liver, and kidneys. Bound to plasma and tissue proteins.
Metabolized by hepatic microsomal enzyme system.
Plasma t ½ is about 25 h. Metabolites excreted in urine and to a lesser extent in the feces. Negligible amount eliminated unchanged in urine.
0.75 to 1 h.
6 to 8 h.
Relief of anxiety; short-term therapy for insomnia; induction of preanesthetic sedation.
Hypersensitivity to barbiturates; history of addiction to sedative-hypnotic drugs; history of porphyria; severe liver impairment; respiratory disease with dyspnea; patients with nephritis.
PO/IM/IV 65 to 200 mg at bedtime.
SedationAdultsPO/IM/IV 30 to 50 mg twice daily or 3 times daily.
ChildrenPO/IM 2 to 6 mg/kg/dose.
Store at room temperature. Do not freeze.
Depressant effects of these drugs may be enhanced.
Anticoagulants, beta-blockers, calcium-channel blockers (eg, verapamil), theophyllinesActivity of these drugs may be reduced.
AnticonvulsantsSerum concentrations of carbamazepine, valproic acid and succinimides may be reduced. Valproic acid may increase barbiturate serum levels.
CorticosteroidsEffectiveness may be reduced.
Estrogens, estrogen-containing oral contraceptivesEffectiveness may be reduced.
Decreased serum bilirubin; false-positive phentolamine test results.
Bradycardia; hypotension; syncope.
Drowsiness; agitation; confusion; headache; hyperkinesia; ataxia; CNS depression; paradoxical excitement; nightmares; psychiatric disturbances; hallucinations; insomnia; dizziness.
Nausea; vomiting; constipation.
Blood dyscrasias (agranulocytosis, thrombocytopenia).
Liver damage.
Hypoventilation; apnea; laryngospasm; bronchospasm.
Hypersensitivity reactions (eg, angioedema, rashes, exfoliative dermatitis); fever; injection site reactions (eg, local pain, thrombophlebitis).
Category D .
Excreted in breast milk.
Safety and efficacy not established in children younger than 6 yr of age.
Reduce dosage.
Use with caution; reduce dosage.
Use with caution; reduce dosage.
Tolerance or psychologic and physical dependence may occur with continued use.
Respiratory depression, CNS depression progressing to Cheyne-Stokes respiration, oliguria, tachycardia, hypotension, hypothermia, coma, shock, cessation of electrical activity in brain (extreme overdose).
Copyright © 2009 Wolters Kluwer Health.